PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Resiniferatoxin has pain-relieving activity superior to capsaicin and is effective for treating osteoarthritis [PMID: 39977586]; clinical trials for diabetic polyneuropathy and postherpetic neuralgia have been pursued [PMID: 9064473].
Extracts of E. resinifera inhibit colon cancer cell lines (DLD-1) by affecting apoptosis, migration, and proliferation [PMID: 38987732].
Total triterpenes (TTE) from Euphorbium showed preventive effects against FCA-induced arthritis in rats [PMID: 36610673].
The protease EuRP-61 prolongs prothrombin (PT) and activated partial thromboplastin (APTT) times and hydrolyzes fibrin clots [PMID: 32781033].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 38534665 (2024) — Chemical Characterization and Biological Properties Assessment of Euphorbia resinifera and Euphorbia officinarum Moroccan Propolis. · Antibiotics (Basel, Switzerland)
- 2.PMID: 38987732 (2024) — Two spurge species, Euphorbia resinifera O. Berg and Euphorbia officinarum subsp. echinus (Hook.f. & Coss.) Vindt inhibit colon cancer. · BMC complementary medicine and therapies
- 3.PMID: 38295538 (2024) — Biochemical characterization of Euphorbia resinifera floral cyathia. · Journal of plant physiology
- 4.PMID: 36014466 (2022) — Antifungal and Cytotoxic Activity of Diterpenes and Bisnorsesquiterpenoides from the Latex of Euphorbia resinifera Berg. · Molecules (Basel, Switzerland)
- 5.PMID: 6746723